drugset / Trial / NCT02448446
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
Phase 1/2
Completed
25 enrolled
South Coast Retina Center; Carson, McBeath, Boswell, Inc.
Doheny Image Reading Center · collabGenentech, Inc. · collabThe Retina Partners · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
Timeline
- Start
- 2015-08
- Primary completion
- 2018-05
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.3 mg | Intravitreal |